Therapeutic Cancer Vaccine Articles & Analysis: Older
87 news found
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. With the rise of antibiotic-resistant bacteria posing a significant threat to global public health, Ace Therapeutics announces its new vaccine development services to ...
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. ...
ByOncoVITA
In vitro diagnostics (IVD) are tests done on samples such as blood or tissue for the purpose of detecting diseases or other conditions. To facilitate efforts on IVD research, the US-based chemical supplier Alfa Chemistry has recently introduced three IVD products for laboratory use, adding to its already diverse range of biological reagents. The biological reagents previously launched by Alfa ...
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (“bYoRNA”) today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (“mRNA”). Dyadic is a global biotechnology company focused on building innovative ...
"End-to-End Support for Your Pharmaceutical Journey", with the commitment to researchers, BOC Sciences will attend the renowned World Vaccine Congress Europe in Barcelona, Spain, from 16 to 19 Octobe World Vaccine Congress Europe has become the world's largest and most established meeting dedicated to vaccines. It brings together the professionals and companies that are shaping the future of ...
Various organic or inorganic materials have been used to prepare nano-drug delivery systems for safe and effective cancer therapy. PLGA-based drug delivery systems have attracted great interest because they can transport different types of drugs, such as hydrophilic or hydrophobic small or large molecules, and protect them from degradation and uncontrolled release. ...
Airfinity announces today the launch of Airfinity IDA (Infectious Disease Analytics) 360, a new platform that will provide a comprehensive overview of vaccine and therapeutics candidates across the full infectious disease landscape. Airfinity IDA 360, a first-of-its-kind product in the health analytics market, will be a centralised source of competitive intelligence, providing clear and near ...
Follows recent financing round led by Novalis LifeSciences LLC, with investors Dr. Marijn Dekkers and Moderna’s co-founder Dr. Kenneth Chien joining the board of directors Strategic focus includes customized lipid nanoparticles (cLNPs) mRNA chemistries and process capabilities as enabling technologies driving company excellence etherna (“the Company”), a leading ...
ByeTheRNA
Service Range MHC Neoepitopes Discovery For the development of therapeutic cancer vaccines and T-cell therapies, as well as an ever-growing neoepitope dataset for client program development, immunogenic neoepitopes are selected, characterized, and monitored in studies. Cancer Vaccine Development Based on pMHC ...
Recent advances in the architecture and scale of AI are leading us from the era of narrowly focused AI (e.g. text auto-complete, immune epitope prediction in a protein sequence, antibody domain detection) to broader models with applications across domains from sales and marketing to medical diagnostics. In protein biochemistry these are the “AIFold” models such as AlphaFold2, ...
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). As communicated on 23 September 2021, ...
Results of an analysis of a previous prevention trial with Diamyd® (GAD-alum) treatment, which indicate a positive and sustained immunomodulating effect after treatment with Diamyd® in healthy children at risk for type 1 diabetes, have been published in the scientific journal Journal of Immunology Research. The analysis was carried out by researchers at Lund University and provides ...
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry the genetic HLA DR3-DQ2 haplotype. DIAGNODE-B (B for “booster”) assesses ...
Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in Stockholm, Sweden. The updated ...
“Through our successful partnership with K2HV, this refinancing and access to additional capital further enables important financial flexibility as we continue our commercial launch of PreHevbrio™ and advance our prophylactic and therapeutic vaccine pipeline,” said Jeff Baxter, VBI’s President and CEO. ...
Biolingus IP II GmbH and the CHA Vaccine Institute Co., Ltd., with support from the Korean biotech company PanGen Biotech Inc., will collaborate to develop a sublingual vaccine for COVID. The project has received research funding from The Research Investment for Global Health Technology Fund (The RIGHT Fund). The RIGHT Fund is a Public-Private Partnership (PPP) funding agency between the ...
An article presenting the 5-month interim results from the open-label trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal Frontiers in Endocrinology. As communicated on December 7, 2021, immunological analyses after 5-months showed that the treatment with Diamyd® induced a ...
Dr. Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. Francis Collins. This summit outlined a path toward innovative, next-generation COVID-19 vaccines and ...
The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which the diabetes vaccine Diamyd® was administered directly into the lymph node of 14 patients aged 30 to 70 years with the autoimmune form of diabetes called LADA (Latent Autoimmune Diabetes in Adults). Analyses also showed a positive immunological ...
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has entered a manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison (Waisman), to manufacture ...